Benzinga | Dec 10, 2021 05:08AM EST

Oppenheimer Initiates Coverage On BioCryst Pharmaceuticals with Outperform Rating, Announces Price Target of $16

Oppenheimer analyst Justin Kim initiates coverage on BioCryst Pharmaceuticals (NASDAQ:BCRX) with a Outperform rating and announces Price Target of $16.